Concentra Biosciences LLC, controlled by San Diego's Tang Capital Partners LP, made an unsolicited offer at $3 per share plus ...

Here's how an activist investor is threatening a Peninsula drug maker's merger plans. And the drama introduces a potential ...

As part of an agreement announced two weeks ago, eye-disease-focused Acelyrin was due to be absorbed into immune-mediated ...

Acelyrin earlier this month agreed to an all-stock merger with fellow immune player Alumis, with their combined cash tiding ...

On February 6, 2025, ACELYRIN announced an agreement to merge with Alumis Inc. (Nasdaq: ALMS) in an all-stock transaction. The transaction is expected to close in the second quarter of 2025, subject ...

The interest from Concentra Biosciences includes an offer to purchase all outstanding shares of ACELYRIN at $3.00 each, plus a contingent value right tied to 80% of net proceeds from potential future ...

Acelyrin (SLRN) “confirmed receipt of an unsolicited indication of interest from Concentra Biosciences, LLC, of which Tang Capital Partners, LP ...

Shares of Acelyrin climbed after the company said it has received an unsolicited indication of interest from Concentra Biosciences for an acquisition at $3 a share. The stock was up 14% at $2.48 in ...

The FDA determined that Novo Nordisk’s obesity and diabetes drugs are no longer in short supply. Elsewhere, Concentra made a ...

Acelyrin (NASDAQ:SLRN) received an unsolicited acquisition offer from Concentra Biosciences, controlled by Tang Capital Partners. The proposal includes a cash payment of $3.00 per share, along with a ...